University of North Carolina Cancer Hospital
Welcome,         Profile    Billing    Logout  
 28 Trials 
31 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Muss, Hyman B
NCT01305954: Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients

Completed
N/A
100
US
UNC Lineberger Comprehensive Cancer Center
Breast Cancer
04/14
09/23
SENSE, NCT04932031: Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy

Terminated
N/A
123
US
Sapere Bio, National Institute on Aging (NIA), University of North Carolina, University of Alabama at Birmingham
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Aging
11/23
11/23
NCT05926024: Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

Recruiting
N/A
200
US
Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes, Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a), Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12), Patient Reported Outcomes PROMIS, Patient Reported Outcomes FACT-Endocrine Symptoms, Patient Reported Outcomes Penn Arthralgia Aging Survey, Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE), p16 tumor suppressor gene
UNC Lineberger Comprehensive Cancer Center
Breast Cancer
01/25
01/25
NCT04292847: LCCC1931:Post-treatment Intervention in Women With Breast Cancer (70y/o+)

Suspended
N/A
100
US
Referrals Recommendations
UNC Lineberger Comprehensive Cancer Center, Breast Cancer Research Foundation, National Cancer Institute (NCI)
Breast Cancer
06/25
06/26
NCT03761706: Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging

Active, not recruiting
N/A
132
US
Engagement in Physical Activity, Questionnaires
UNC Lineberger Comprehensive Cancer Center, Breast Cancer Research Foundation
Breast Cancer
08/24
02/25
NCT01137825: Registry of Older Patients With Cancer

Recruiting
N/A
3000
US
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
07/30
12/30
O'Neil, Bert H
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
NCT05249101: A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

Recruiting
1/2
70
US
Ivaltinostat, Capecitabine, Xeloda
CG Pharmaceuticals, Inc
Metastatic Pancreatic Adenocarcinoma
02/26
06/26
NCT04657068: A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Recruiting
1/2
547
Europe, US
ART0380, Gemcitabine, Gemzar, Irinotecan, Camptosar, Camptothecin-11
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
06/25
GV20-0251-100, NCT05669430: A Study of GV20-0251 Monotherapy and GV20-0251 in Combination with Pembrolizumab in Participants with Solid Tumor Malignancies

Recruiting
1/2
365
US
GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], MK-3475
GV20 Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, PMMR/MSS Adenocarcinoma of the Colon or Rectum, Cutaneous Melanoma, Non-Small Cell Lung Cancer
12/26
09/27
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruiting
1
500
Europe, Japan, US, RoW
LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Eli Lilly and Company
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
06/20
12/27
NCT04965818: Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Terminated
1
38
US
Futibatinib and Binimetinib
Taiho Oncology, Inc.
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation
06/23
09/23
SGNB7H4V-001, NCT05194072: A Study of SGN-B7H4V in Advanced Solid Tumors

Active, not recruiting
1
572
Europe, Canada, US
SGN-B7H4V, Pembrolizumab, Keytruda
Seagen Inc.
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
11/27
11/27
Weiss, Jared
WAVE, NCT04078152 / 2019-001402-20: Durvalumab Long-Term Safety and Efficacy Study

Completed
4
163
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736
AstraZeneca, Iqvia Pty Ltd, Parexel, Medidata Solutions, CISCRP
Solid Tumor
10/22
10/24
NCT01612351: Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Active, not recruiting
2
40
US
Carboplatin, Paraplatin, Paclitaxel, Taxol, Lapatinib, Tykerb, Cisplatin, Platinol, Ipsilateral Radiation, Radiation therapy, Bilateral Radiation, Transoral Surgery, Surgery
UNC Lineberger Comprehensive Cancer Center, GlaxoSmithKline
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
11/16
11/31
NCT03174275: Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Active, not recruiting
2
39
US
Durvalumab, MEDI4736, Carboplatin, Paraplatin, Nab-paclitaxel, Abraxane, Cisplatin, Surgical resection, IMRT, Intensity-modulated radiation therapy
UNC Lineberger Comprehensive Cancer Center, AstraZeneca, Celgene
Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer, Lip Cancer, Esophageal Cancer
02/22
02/27
NCT02609503: Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin

Checkmark For stage III-IV head and neck squamous cell carcinoma
Jun 2020 - Jun 2020: For stage III-IV head and neck squamous cell carcinoma
Completed
2
29
US
Pembrolizumab, Keytruda, Intensity Modulated Radiation Therapy, IMRT
UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Head and Neck Cancer
12/19
11/23
VERSATILE-002, NCT04260126: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC

Checkmark Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Feb 2022 - Feb 2022: Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Active, not recruiting
2
95
Europe, US
Pembrolizumab (KEYTRUDA®) and PDS0101
PDS Biotechnology Corp., Merck Sharp & Dohme LLC
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
06/25
06/25
NCT05578326: Study of Trilaciclib and Lurbinectidin

Recruiting
2
30
US
Trilaciclib, Lurbinectedin
UNC Lineberger Comprehensive Cancer Center, G1 Therapeutics, Inc.
Lung Cancer, Small-cell Lung Cancer
12/25
12/27
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
NCT03917381 / 2018-003402-63: GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active, not recruiting
1/2
429
Europe, US, RoW
Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Genmab, BioNTech SE
Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer
02/26
02/26
NCT05375994: Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Active, not recruiting
1/2
85
US
avutometinib (VS-6766) and adagrasib, KRAS G12C Inhibitor, adagrasib, KRAZATI®
Verastem, Inc., Mirati Therapeutics Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
12/24
01/25
SKYBRIDGE, NCT05652686: A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the Study)

Recruiting
1/2
203
US
Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab
Phanes Therapeutics, Hoffmann-La Roche
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
12/27
08/28
NCT06096038: Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Recruiting
1/2
33
US
Cyclophosphamide, Cycloblastin, Cytoxan, Endoxan, Neosar, Procytox, Revimmune, Fludarabine, Fludara, Fludarabine Phosphate, Cell Therapy
UNC Lineberger Comprehensive Cancer Center, Bellicum Pharmaceuticals, University Cancer Research Fund at Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Head and Neck Cancer, Relapse, Recurrent, Refractory Cancer
09/26
09/28
PANDA-VAC, NCT04266730: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

Not yet recruiting
1
6
US
PANDA-VAC, Personalized and adaptive neoantigen dose-adjusted vaccine, Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
06/26
06/33
NCT05911308: Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Recruiting
1
24
US
Durvalumab, Imfinzi, Carboplatin, Paraplatin, Abequolixron, RGX 104, RGX-104, RGX104, SB-742881, Abraxane, Paclitaxel albumin-bound, Nab-paclitaxel, Pemetrexed, Alimta
UNC Lineberger Comprehensive Cancer Center, AstraZeneca, Rgenix, Inc.
Non-Small Cell Lung Cancer
12/25
12/26
NCT05620342: Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Recruiting
1
24
US
iC9.GD2.CAR.IL-15 T Infusion
UNC Lineberger Comprehensive Cancer Center, Bellicum Pharmaceuticals, United States Department of Defense
Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
02/25
02/27
NCT05973487: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Recruiting
1
100
US
TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
12/26
12/26
NCT05812027: A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Recruiting
N/A
650
US
Tumor and HLA Profiling
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, Melanoma, Ovarian Cancer, HPV16 Related Cancers
01/26
01/27
Nyrop, Kirsten A
SENSE, NCT04932031: Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy

Terminated
N/A
123
US
Sapere Bio, National Institute on Aging (NIA), University of North Carolina, University of Alabama at Birmingham
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Aging
11/23
11/23
NCT03761706: Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging

Active, not recruiting
N/A
132
US
Engagement in Physical Activity, Questionnaires
UNC Lineberger Comprehensive Cancer Center, Breast Cancer Research Foundation
Breast Cancer
08/24
02/25

Download Options